Novonesis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Novozymes hat ein Gesamteigenkapital von DKK14.4B und eine Gesamtverschuldung von DKK7.4B, wodurch sich der Verschuldungsgrad auf 51.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen DKK28.4B bzw. DKK14.0B. Novozymes Das EBIT des Unternehmens beträgt DKK4.5B, so dass der Zinsdeckungsgrad 53.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von DKK1.1B.

Wichtige Informationen

18.1%

Verhältnis von Schulden zu Eigenkapital

€1.99b

Verschuldung

Zinsdeckungsgrad	15.7x
Bargeld	€260.80m
Eigenkapital	€11.01b
Gesamtverbindlichkeiten	€4.25b
Gesamtvermögen	€15.25b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NZYMDie kurzfristigen Aktiva des Unternehmens (DKK9.5B) übersteigen seine kurzfristigen Passiva (DKK7.3B).

Langfristige Verbindlichkeiten: NZYMDie kurzfristigen Vermögenswerte des Unternehmens (€1.8B) decken seine langfristigen Verbindlichkeiten (€2.6B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NZYMDie Nettoverschuldung im Verhältnis zum Eigenkapital (15.7%) wird als zufriedenstellend angesehen.

Schulden abbauen: NZYM Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 36.2% auf 18.1% zurückgegangen.

Schuldendeckung: NZYMDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (56%).

Zinsdeckung: NZYMDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (53.8x Coverage) gut gedeckt.

Novonesis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

New minor risk - Share price stability

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr.2.19 (vs kr.2.92 in 2Q 2022)

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

New 90-day high: €51.50

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

New 90-day low: €45.33

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.